


Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

### Data Insights: Covid-2019 Monitor

Saturday, February 5, 2022

### The global scorecard




Cases: 7-day average and daily Deaths: Daily

#### For more information contact us:

Donald Luskin: 214 550 2121 <u>don@trendmacro.com</u> Thomas Demas: 704 552 3625 <u>tdemas@trendmacro.com</u>


Copyright 2022 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

| Rolling out the vaccines in the US and the world |  |   |  |            |  |         |                   |                 |   |          |         |  |
|--|--|---|--|------------|--|---------|-------------------|-----------------|---|----------|---------|--|
| Administered                                     | Cumu                                     | lative  |  |            |  |         | То                | day             | Immunity                                | Full     | Partial |  |
| Doses  | 55                                       | 555,648,330   |  |            |  |         | +0.603            | million         | US                                      | 63.8%    | 75.5%   |  |
| Boosters   | 90,488,390                               |   |  |            |  |         | +0.310            | million         | UK                                      | 71.1%    | 76.8%   |  |
|  | One dose                                 |   | % Pop  | Imm        | nune   | % рор   | New imm           | une today       | France                                  | 76.6%    | 79.8%   |  |
| Total population                                 |  | 8,256,682   | 77%  |            | 18,550,587   | 65%     |                   | ,<br>million    | Spain                                   | 82.0%    | 87.6%   |  |
| Age 12 to 17                                     |  | 7,026,583   | 67%  |            | 14,398,732   | 57%     | +0.018            | million         | Germany                                 | 73.7%    | 75.3%   |  |
| Age 18 to 64                                     | 174,267,221                              |   | 86%  | 86% 147,53 |  | 73%     | +0.067            | million         | Italy                                   | 77.0%    | 83.6%   |  |
| Age 65 and over                                  |  | 57,982,449  |  | 50,144,607 |  | 92%     |                   | million         | Australia                               | 78.6%    | 84.5%   |  |
| ا&ا  | L&L                                      |   |  |            | , ,  |         |                   |                 | Israel                                  | 65.7%    | 72.0%   |  |
| 3%   |  |   |  |            |  |         |                   |                 | Canada                                  | 79.6%    | 85.1%   |  |
|  |  | State<br>At least partial immunity<br>as % population |  |            |  |         |                   |                 | Japan                                   | 79.2%    | 80.4%   |  |
| Moderna  | Sta                                      |   |  | i -        |  |         |                   |                 | Africa                                  | 10.9%    | 16.1%   |  |
| 38%  | At least part                            |   |  |            |  |         |                   |                 | India                                   | 52.0%    | 68.1%   |  |
| Pfizer<br>59%                                    |  |   |  | le         |  |         |                   |                 | Brazil                                  | 70.4%    | 80.3%   |  |
| 59%  | Full immunity                            |   |  |            |  |         |                   |                 | China                                   | 85.0%    | 87.7%   |  |
| AK   | as % population                          |   | Wors   | st         |  |         |                   |                 | Global data differ                      |          |         |  |
| 68.0%  | "Immunity" = two                         | doses   |  |            | WI   |         | As of Feb 4       |                 | Г                                       | ME       |         |  |
| 59.8%  |  |   |  |            | 70.5%  |         |                   |                 |   | 88.7%    |         |  |
| 30.070   |  |   |  |            | 63.8%  |         |                   |                 |   | 77.7%    |         |  |
| WA   | ID                                       | MT  | ND   | MN         | IL   | MI      | 1                 | NY              | VT                                      | NH       |         |  |
| 78.9%  | 59.7%                                    | 63.9%   | 64.1%  | 73.7%      | 75.4%  | 65.4%   |                   | 87.8%           | 92.3%                                   | 95.0%    |         |  |
| 70.2%  | 52.4%                                    | 55.4%   | 54.1%  | 67.3%      | 66.3%  | 58.4%   |                   | 74.4%           | 79.5%                                   | 69.0%    |         |  |
| OR   | NV                                       | WY  | SD   | IA         | IN   | OH      | PA                | NJ              | MA                                      | 00.070   |         |  |
| 76.3%  | 73.1%                                    | 57.4%   | 74.1%  | 66.8%      | 60.1%  | 62.4%   | 82.3%             | 87.8%           | 95.0%                                   |          |         |  |
| 68.0%  | 58.7%                                    | 50.0%   | 59.1%  | 60.5%      | 53.4%  | 57.0%   | 66.0%             | 73.2%           | 76.6%                                   |          |         |  |
| CA   | UT                                       | CO  | NE   | MO         | KY   | WV      | VA                | MD              | CT                                      | RI       | ŀ       |  |
| 80.7%  | 70.1%                                    | 77.6%   | 68.8%  | 64.8%      | 64.8%  | 63.7%   | 83.4%             | 83.9%           | 92.8%                                   | 94.9%    |         |  |
| 69.3%  | 60.9%                                    | 68.4%   | 61.8%  | 54.5%      | 55.8%  | 56.3%   | 70.8%             | 72.9%           | 76.8%                                   | 79.3%    |         |  |
| 00.070   | AZ                                       | NM  | KS   | AR         | TN   | NC      | SC                | DC              | DE                                      | 7 0.0 70 |         |  |
|  | 70.4%                                    | 84.8%   | 72.7%  | 65.2%      | 60.8%  | 81.2%   | 65.8%             | 93.6%           | 80.7%                                   |          |         |  |
|  | 59.0%                                    | 68.6%   | 59.3%  | 52.9%      | 52.9%  | 58.6%   | 55.1%             | 70.3%           | 66.5%                                   |          |         |  |
|  | 00.070                                   | 00.070  | OK   | LA         | MS   | AL      | GA                | 10.070          | 00.070                                  |          |         |  |
|  |  |   | 69.4%  | 59.6%      | 58.3%  | 61.3%   | 63.8%             |                 |   |          |         |  |
| HI   |  |   | 55.3%  | 51.9%      | 50.3%  | 49.6%   | 53.0%             |                 |   |          |         |  |
| 85.3%  |  |   | TX   | 01.070     | 00.070   | 10.0 /0 | 00.070            | FL              | l ľ                                     | PR       |         |  |
| 76.2%  |  |   | 69.9%  |            |  |         |                   | 77.3%           |   | 93.6%    |         |  |
| 10.270   |  |   | 59.1%  |            |  |         |                   | 65.2%           |   | 79.8%    |         |  |
|  |  |   | 00.170   |            |  |         |                   | 00.2 /0         |   | 70.070   |         |  |
| The demographics of                              | US vaccinat                              | ion   |  |            |  |         |                   |                 |   |          |         |  |
| 70% ¬  |  |   | 80%  |            |  |         | 100%              |                 |   |          |         |  |
| 65.6% of females immunized                       |  |   | 61.0% of whites immunized                      |            |  |         |                   | 13.3% of ag     | e <12 immuni                            | zed      |         |  |
| 60% - 61.4% of mates                             |  |   | 70% 51.2% of African Americans                 |            |  |         | 90%               | 54.4% 12-15     |   |          |         |  |
|  |  |   | 60% 64.9% of Hispapics                         |            |  |         | 80%               |                 |   |          |         |  |
| 50%  |  |   | 76.2% of Asians                                |            |  |         | 70% -             | 60.9% 18-2      | 4                                       |          |         |  |
| 40%  |  |   | 50%  |            |  |         | 60% -             | 60% 64:8% 5-39  |   |          |         |  |
|  |  |   | 40%  |            |  |         | 50% - 72.9% 40-49 |                 |   |          |         |  |
| 30% -  |  |   | 2007   |            |  |         | 40%79.6% 50-64    |                 |   |          |         |  |
| 20%  |  |   | 30%  |            |  |         | 30% 90.8% 65/74   |                 |   |          |         |  |
| 20%  |  |   | 20%  |            |  |         | 85.1% 75.         |                 |   |          |         |  |
| 10%  |  |   | 10%  |            |  |         | 20% -             |                 |   |          |         |  |
|  | 10%                                      |   |  |            | 10%  |         |                   |                 |   |          |         |  |
| ļ  |  |   | -  | <u> </u>   |  | · · ·   | +                 | <u></u>         | <u> </u>                                |          |         |  |
| 122 122 122 122                                  | 2161202 1161201 1201 1201 1201 1201 1201 |   |  |            | 51/6 <sup>221</sup> 6 <sup>221</sup> |         |                   |                 | 216220 2161201 0221 0221 0201 0201 0201 |          |         |  |
| 5/10, 5/20, 4/20, 0/201, C                       | 3/20/ 0/20/ 2/20                         | )/  | 1, 1, 10, 5/10, 11, 2, 2/10, 8/10, 0/10, 5/10, |            |  |         | 2/20/ 2/2         | 0, 41201. CIZO1 | 8/201,01201,2                           | 1201     |         |  |
|  |  | rld in Da   |  |            |  | 10      | <b>y</b> .        |                 | <b>y</b> Y                              |          |         |  |

Source: <u>CDC</u>, <u>CDC</u>, <u>Our World in Data</u>, TrendMacro calculations



National and state-by-state data do not line up because of different sources

900.00

800.00

400.00

90bp

80bp

70bp

60bp


50bp


40bp


30bp


20bp

10bp










Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

# Recommended reading

#### <u>The British Medical Journal Story That Exposed</u> Politicized "Fact-Checking"

Matt Taibbi *TK News* February 1, 2022

### Tear Down These Masks

James Freeman *Wall Street Journal* February 4, 2022

# 'Democrats woke a sleeping giant': Why parents say

### they've had enough

Story Hinckley *Christian Science Monitor* February 3, 2022

#### Kids Full of Life, Adults Obsessed with Death

Jeffrey H. Anderson *City Journal* February 3, 2022

#### Fauci is the villain in new GOP campaign ads Stephanie Murray *Politico* February 4, 2022

#### <u>Covid-19 Commission Modeled on 9/11 Inquiry</u> Draws Bipartisan Backing

Sheryl Gay Stolberg New York Times February 4, 2022

#### Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness Amiel A. Dror et al PLOS One


*PLOS One* February 3, 2022

# How a War on 'Misinformation' Led To a Coronavirus

### <u>Tragedy</u>


Bret Swanson *RealClear Markets* February 4, 2022

# Meme of the day




### COVID GUIDANCE

Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP




# The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale*

Source: Johns Hopkins, TrendMacro calculations




# The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality, log scale*

Source: Johns Hopkins, TrendMacro calculations




## Source: Johns Hopkins, TrendMacro calculations

Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Johns Hopkins, TrendMacro calculations


Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst




Source: Covid Act Now, TrendMacro calculations

From Ground Zero to the Rio Grande


Cases: 7-day average and daily Deaths: Daily



Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations




Patient zero... and then everyone else

Cases: 7-day average and daily Deaths: Daily

Source: Johns Hopkins, TrendMacro calculations


Impact in the largest economies Cases: 7-day average and daily



Source: Johns Hopkins, TrendMacro calculations

Impact in The Anglosphere Cases: 7-day average and daily Deaths: Daily 250,000 18% **United Kingdom** As of Feb 4 16% 200,000 2672.31 bp of population infected 14% Daily new cases and deaths 23.79 bp of population fatalities 12% 17,810,151 cases cumulative 40.5 median population age 150,000 +82,470 cases today 99.5% Omicron variant share 10% 71.1% total population immunized Cume fatality rate 0.89% 8% 100,000 6% 2-week fatality rate 0.29% 4% 50,000 158,521 deaths cumulative +255 deaths today 2% 0% Mar '20 Jul '20 Sep '21 Jan '22 Jan '20 May '20 Sep '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Nov '21 70,000 10.0% Canada 9.0% 60,000 3,109,754 cases cumulative 820.63 bp of population infected +14,113 cases today 8.0% 9.11 bp of population fatalities Daily new cases and deaths 50,000 7.0% 40.8 median population age Cume fatality rate 1.11% Case 6.0% 40,000 96.5% Omicron variant share 79.6% total population immunized 5.0% 2-week fatality rate 0.45% 30,000 4.0% rat 34,536 deaths cumulative 3.0% 20,000 +158 deaths today 2.0% 10,000 1.0% 0.0% Jan '20 Mar '20 May '20 Jul '20 Sep '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Nov '21 Jan '22 200,000 4.5% 180,000 Australia 4.0% 2,704,275 cases cumulative 97,47 bp of population infected 160,000 +27,336 cases today 3.5% 10 bp of population fatalities 40,000 120,000 3.0% 37.9 median population age 93.4% Omicron variant share 2-week fatality rate 0.09% 2.5% ¥00,000 78.6% total population immunized Cume fatality rate 0.15% 2.0% 1000,08 € 1.5% 1.0% 40,000 4,154 deaths cumulative +81 deaths today 0.5% 20,000 0.0% Nov '21 Jan '22 Jan '20 Mar '20 May '20 Jul '20 Sep '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Sep '21






Source: Johns Hopkins, TrendMacro calculations


40,000 3.0% South Korea As of Feb 4 35,000 2.5% 187.30 bp of population infected ള്40,000 1.32 bp of population fatalities 971,018 cases cumulative 8005 5,000 2.0% +36,362 cases today 41.8 median population age Cume fatality rate 0.71% g20,000 1.5% 33.4% total population immunized ≧ 15,000 rate 2-week fatality rate 0.50% 1.0% 1111111111 10,000 6,858 deaths cumulative 0.5% +22 deaths today 5,000 0.0% Jul '20 Sep '20 Jan '21 Jan '20 Mar '20 May '20 Nov '20 Mar '21 May '21 Jul '21 Sep '21 Nov '21 Jan '22 14,000 0.6% Singapore 12,000 0.5% 665.69 bp of population infected 379,681 cases cumulative Daily new cases and deaths 8,000 6,000 4,000 4,000 0.18 bp of population fatalities +13,208 cases today 0.4% 34.6 median population age Cume fatality rate 0.23% 94:3% Omicron variant share 87.8% total population immunized 2-week fatality rate 0.13% 0.3% 866 deaths cumulative +6 deaths today 0.2% 0.1% 2,000 0.0% Jan '22 Mar '20 Sep '20 Jan '20 May '20 Jul '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Nov '21 60,000 14% Sweden 12% 50,000 2260.21 bp of population infected 2,287,785 cases cumulative +28,129 cases today 15.98 bp of population fatalities Daily new Cases and deaths 20,000 pm 10% 40.9 median population age Cume fatality rate 0.71% 96.4% Omicron variant share ase fatality rate 8% 74.1% total population immunized 2-week fatality rate 0.20% 6% 16,180 deaths cumulative +80 deaths today 4% 10,000 2% 0% May '20 Jul '20 Sep '20 Jan '20 Mar '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Nov '21 Jan '22 Source: Johns Hopkins, TrendMacro calculations


Impact in the BRICs ex-China Cases: 7-day average and daily Deaths: Daily




Impact in the Middle East and Africa

Cases: 7-day average and daily Deaths: Daily







Source: Johns Hopkins, TrendMacro calculations